Medical Oncologist
Vorrias Eleftherios
Dr. Eleftherios Vorrias is a Consultant Medical Oncologist with his main areas of interest being thoracic and gastrointestinal malignancies, as well as sarcomas. He was born and raised on the Greek island of Chios, studied Medicine at the Aristotle University of Thessaloniki and completed his residency in Medical Oncology at the University Clinic of the Crete University, where he also is a PhD candidate.
He is specialised in administering systemic treatments for malignant diseases (chemotherapy, immunotherapy, targeted therapies) and also maintaining quality of life and palliative care for oncological patients.
-
Education / Academic Experience
-
Professional experience
-
Certifications / Courses
-
Publications
-
Professional Memberships
2012 – Undergraduate Medical Degree – Aristotle University of Thessaloniki
2012 – Medical Elective – University of Glasgow
2013-2014 – ECFMG USA certification
2014 – Medical Observership – East Carolina University
2015 – Resident of Internal Medicine – Chios General Hospital ‘Skylitsion’
2018 – Resident of Internal Medicine – Heraklion University Hospital
2019 – Resident of Medical Oncology – Heraklion University Hospital
2020 – Initiation of Doctoral Thesis about the prognostic and predictive value of a miRNA signature, for early stage NSCLC after surgery
2022 – Greek Academy of Medical Oncology
2012 – Army Doctor – 3rd Special Forces Unit
2015 – Resident of Internal Medicine – Chios General Hospital ‘Skylitsion’
2017 – Rural Doctor – Kalimassia rural medical center
2018 – Resident of Internal Medicine – Heraklion University Hospital
2019 – Resident of Haematology – Heraklion University Hospital
2019 – Resident of Medical Oncology – Heraklion University Hospital
2023 – Consultant of Medical Oncology – German Medical Institute
ECFMG certified
ACLS / BLS certified
Greek Academy of Medical Oncology
Prognostic role of immune checkpoints mRNA expression in peripheral blood of non-small cell lung cancer patients treated with immune checkpoint inhibitors (2022) – Annals of Oncology, doi:10.1016/j.annonc.2022.07.1198
Monitoring of PD-L1 expression on circulating immune cells of patients with small cell lung cancer (SCLC) receiving first line treatment: Prognostic implications (2022) – Annals of Oncology, doi: 10.1016/j.annonc.2022.02.181
Assessment of PD-L1 expression on circulating tumor cells (CTCs) and immune cells in peripheral blood of patients with small cell lung cancer (SCLC) (2021) – Annals of Oncology, doi: 10.1016/j.annonc.2021.08.237
Intrameningioma metastasis: A case-based literature review (2021) – J Clin Neurosci., doi: 10.1016/j.jocn.2021.08.028
MicroRNA expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer (2021) – The 1st Electronic Conference on Cancers, Exploiting Cancer Vulnerability by Targeting the DNA Damage Response, doi: 10.3390/IECC2021-09206
Detection of KRAS G12/G13 Mutations in Cell Free-DNA by Droplet Digital PCR, Offers Prognostic Information for Patients with Advanced Non-Small Cell Lung Cancer (2020) – Cells (9), doi: 10.3390/cells9112514
Member of:
- ESMO
- ASCO
- EOPE
- EOSSO
- EMKAPES
